November 2009 Volume 27 Number 11, pp 959 - 1058
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=26&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=105&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=162&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=91&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Direct PCR from various tissues
http://links.ealert.nature.com/ctt?kn=39&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Finnzymes' Direct PCR approach allows DNA amplification directly from source materials such as plants, animal tissues and blood. No DNA isolation is required prior to PCR. Short and simple protocols allow results in as little as 30-40 min. Take the direct route from sample to results: Finnzymes Direct PCR
http://links.ealert.nature.com/ctt?kn=39&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
STOP CLONING!
Buy pre-cloned promoters and 3'UTRs delivered in luciferase reporter vectors to measure promoter induction and miRNA function. Quantify promoter activation across any pathway including our experimentally-validated pathways regulated by nuclear receptors, CREB NFkB, P53 and more! Visit SwitchGear Genomics and explore our genome-wide, assay-ready promoter and UTR reporters.
http://links.ealert.nature.com/ctt?kn=128&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Workshop on 'Interactomics : at the crossroads of biology and bioinformatics'.
Don't miss the Inserm workshop n°203 on protein-protein interactions networks.
March 30th - April 1st 2010 - St Raphael (France).
For more information, please visit our website:
http://links.ealert.nature.com/ctt?kn=81&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
or contact us: mailto:ateliers@inserm.fr
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
Natureevents Directory 2010
Want to inform a potential one million scientists about your scientific events, courses and conferences?
Natureevents Directory 2010 is now in its 11th year.
Click here to find out how to be included.
http://links.ealert.nature.com/ctt?kn=90&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLES FROM SciBX
Autoimmune disease: Treating MS with hypertension drugs
FULL TEXT: www.nature.com/scibx/journal/v2/n35/full/scibx.2009.1329.html
PDF: www.nature.com/scibx/journal/v2/n35/pdf/scibx.2009.1329.pdf
Musculoskeletal disease: Reversing osteoarthritis
FULL TEXT: www.nature.com/scibx/journal/v2/n34/full/scibx.2009.1297.html
PDF: www.nature.com/scibx/journal/v2/n34/pdf/scibx.2009.1297.pdf
Inflammation: Treating cat allergies
FULL TEXT: www.nature.com/scibx/journal/v2/n32/full/scibx.2009.1230.html
PDF: www.nature.com/scibx/journal/v2/n32/pdf/scibx.2009.1230.pdf
Endocrine disease: Treating type 2 diabetes
FULL TEXT: www.nature.com/scibx/journal/v2/n31/full/scibx.2009.1198.html
PDF: www.nature.com/scibx/journal/v2/n31/pdf/scibx.2009.1198.pdf
ACCESS TO MORE THAN 30 FREE ARTICLES from the SciBX Cover Story Archive:
http://links.ealert.nature.com/ctt?kn=27&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Joining forces p959
doi:10.1038/nbt1109-959
Similar to outsourcing in the corporate world, technology incubators are beginning to look beyond their own borders to find technology.
http://links.ealert.nature.com/ctt?kn=17&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
NEWS
----------------------
Pfizer settles largest ever fraud suit for off-label promotion pp961 - 962
Mark Ratner
doi:10.1038/nbt1109-961
http://links.ealert.nature.com/ctt?kn=20&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Surprise ruling eases diagnostic makers' fears p963
Emily Waltz
doi:10.1038/nbt1109-963b
http://links.ealert.nature.com/ctt?kn=10&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
WHO guidelines presage US biosimilars legislation? pp963 - 965
John Hodgson
doi:10.1038/nbt1109-963a
http://links.ealert.nature.com/ctt?kn=14&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Variant predicts HCV response p964
Mike May
doi:10.1038/nbt1109-964a
http://links.ealert.nature.com/ctt?kn=94&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
First-to-market loses grip p964
Bob Carlson
doi:10.1038/nbt1109-964b
http://links.ealert.nature.com/ctt?kn=97&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Genzyme backs Osiris, despite Prochymal flop pp966 - 967
Malorye Allison
doi:10.1038/nbt1109-966
http://links.ealert.nature.com/ctt?kn=120&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
One shot at H1N1 p967
Wendy Wolfson
doi:10.1038/nbt1109-967a
http://links.ealert.nature.com/ctt?kn=118&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
'GMO-free' logos p967
Emily Waltz
doi:10.1038/nbt1109-967b
http://links.ealert.nature.com/ctt?kn=123&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Genentech obtains proof of concept for hedgehog inhibition pp968 - 969
Cormac Sheridan
doi:10.1038/nbt1109-968
http://links.ealert.nature.com/ctt?kn=109&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Puerto Rico GM crop haven p970
Veronica Guerrero
doi:10.1038/nbt1109-970a
http://links.ealert.nature.com/ctt?kn=116&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Kick-start for Canada's agbio p970
John Hodgson
doi:10.1038/nbt1109-970b
http://links.ealert.nature.com/ctt?kn=114&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Courts upbraid USDA for 'lax review' of GM crops p970
Emily Waltz
doi:10.1038/nbt1109-970c
http://links.ealert.nature.com/ctt?kn=64&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Q&A
Steve Reed pp971 - 972
Charlotte Schubert
doi:10.1038/nbt1109-971
Steve Reed believes the organization he has founded has the potential to radically increase the developing world's access to vaccines for neglected diseases. The efforts of the Seattle-based Infectious Disease Research Institute (IDRI), which operates as a not-for-profit biotech company, may start to pay off during the H1N1 'swine' flu pandemic. IDRI developed an adjuvant to boost the effectiveness and supplies of flu vaccines and is making the technology available to vaccine manufacturers in developing nations. Charlotte Schubert talks to Reed about how IDRI, a 90-person operation with a $19 million annual budget, could have such a big impact.
http://links.ealert.nature.com/ctt?kn=68&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
DATA PAGE
Biotech strikes back in Q3 p973
Walter Yang
doi:10.1038/nbt1109-973
http://links.ealert.nature.com/ctt?kn=53&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
NEWS FEATURES
Whatever happened to GM wheat? pp974 - 976
Jeffrey L Fox
doi:10.1038/nbt1109-974
Agribusiness is taking another run at transgenic wheat after shelving its programs five years ago because of concerns from farmers, trade organizations and even state governments about market acceptance. Will there be a market this time? Jeffrey Fox investigates.
http://links.ealert.nature.com/ctt?kn=49&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
The gold rush for induced pluripotent stem cells pp977 - 979
Sarah Webb
doi:10.1038/nbt1109-977
As the first commercial ventures are formed around induced pluripotent stem (iPS) cell research, who will have the freedom to operate commercially remains a big unknown. Sarah Webb reports.
http://links.ealert.nature.com/ctt?kn=51&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
New Paper Finds Microdroplet PCR Well Suited
For Sequence-Based Association Studies
In the study, Microdroplet-based PCR Enrichment for Large-Scale
Targeted Sequencing, lead author Kelly Frazer reports that the
RainDance technology demonstrated even coverage, high specificity,
and very low allelic bias, enabling large scale resequencing studies.
Learn more: http://links.ealert.nature.com/ctt?kn=22&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=====================================================================
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
The valuation high ground
Jeffrey J Stewart and Ben Bonifant
doi:10.1038/bioe.2009.9
Holding the valuation high ground allows a biotech company to get the most value from potential partners. Here is how to establish and defend financial valuation.
http://links.ealert.nature.com/ctt?kn=86&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
The market value of GM products p984
Rob Carlson
doi:10.1038/nbt1109-984a
http://links.ealert.nature.com/ctt?kn=85&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Accreditation and attribution in data sharing pp984 - 985
Gudmundur A Thorisson
doi:10.1038/nbt1109-984b
http://links.ealert.nature.com/ctt?kn=83&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
COMMENTARY
----------------------
How Tysabri survived p986
Brady Huggett
doi:10.1038/nbt1109-986
Most drugs withdrawn from the market because of serious toxicities never make it back. But Biogen Idec succeeded in getting its multiple sclerosis (MS) drug Tysabri reintroduced in less than 16 months.
http://links.ealert.nature.com/ctt?kn=76&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
FEATURES
----------------------
What's fueling the biotech engine - 2008 pp987 - 993
Saurabh Aggarwal
doi:10.1038/nbt1109-987
Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.
http://links.ealert.nature.com/ctt?kn=74&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
PATENTS
The role of patents in biodiversity conservation pp994 - 995
Charles Lawson
doi:10.1038/nbt1109-994
Patents may not establish clear property and use rights and this may promote biodiversity destruction and decline. What is needed are schemes for patents to suit conservation and sustainable-use objectives.
http://links.ealert.nature.com/ctt?kn=71&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Recent patent applications in biological imaging p996
doi:10.1038/nbt1109-996
http://links.ealert.nature.com/ctt?kn=29&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
JUST WHAT YOU'D EXPECT FROM THE GLOBAL CENTRIFUGATION LEADER
Beckman Coulter delivers powerful centrifuge solutions that keep you
at the forefront of discovery. From intelligent centrifuge systems and
versatile rotors to innovative labware and more, we offer unparalleled
efficiency, productivity and safety in your lab. Learn what six decades
of innovation can do for you.
=====================================================================
----------------------
NEWS AND VIEWS
----------------------
Watching reprogramming in real time pp997 - 998
Deepa Subramanyam and Robert Blelloch
doi:10.1038/nbt1109-997
As a differentiated cell proceeds toward the pluripotent state, markers turn on and off in an orderly fashion.
http://links.ealert.nature.com/ctt?kn=30&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Targeted sequencing with microfluidics pp998 - 999
Ewen F Kirkness
doi:10.1038/nbt1109-998
Combining microdroplet PCR with flow-cell technologies provides a novel approach for sequencing thousands of genomic targets.
http://links.ealert.nature.com/ctt?kn=5&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
A systems view of host defense pp999 - 1001
Daniel E Zak and Alan Aderem
doi:10.1038/nbt1109-999
Large-scale perturbations unravel the complex networks of activated dendritic cells.
http://links.ealert.nature.com/ctt?kn=9&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Mapping duplicated sequences pp1001 - 1002
Derek Y Chiang and Steven A McCarroll
doi:10.1038/nbt1109-1001
Duplicated genomic regions are accurately resolved using an optimized algorithm for mapping reads from next-generation sequencers.
http://links.ealert.nature.com/ctt?kn=13&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p1003
Laura De Francesco, Markus Elsner, Peter Hare and Craig Mak
doi:10.1038/nbt1109-1003
http://links.ealert.nature.com/ctt?kn=45&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
ANALYSIS
An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer pp1005 - 1011
Xiao-Song Wang et al.
doi:10.1038/nbt.1584
Abstract: http://links.ealert.nature.com/ctt?kn=157&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=35&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
RESEARCH
----------------------
REVIEW
The challenges of sequencing by synthesis pp1013 - 1023
Carl W Fuller et al.
doi:10.1038/nbt.1585
Abstract: http://links.ealert.nature.com/ctt?kn=161&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=38&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
ARTICLE
Microdroplet-based PCR enrichment for large-scale targeted sequencing pp1025 - 1031
Ryan Tewhey et al.
doi:10.1038/nbt.1583
In many sequencing applications, it is sufficient to sequence selected portions of a genome rather than the complete genome. Tewhey et al. describe an approach for massively parallel genome targeting that relies on PCR in microdroplets generated by a microfluidic device.
Abstract: http://links.ealert.nature.com/ctt?kn=160&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=7&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
LETTERS
Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells pp1033 - 1037
Elayne M Chan et al.
doi:10.1038/nbt.1580
Methods for reprogramming human cells are unable to prospectively distinguish bona fide induced pluripotent stem (iPS) cells from partially reprogrammed cells. Using live imaging to monitor cell fate, Chan et al. identify a set of markers that allows identification of rare iPS cells within a heterogeneous cell population.
Abstract: http://links.ealert.nature.com/ctt?kn=155&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=4&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Transcriptional analysis of intracytoplasmically stained, FACS-purified cells by high-throughput, quantitative nuclease protection pp1038 - 1042
Susanne Pechhold et al.
doi:10.1038/nbt.1579
Cells that have been purified by FACS using intracellular markers are not amenable to gene expression analysis by conventional methods. Pechhold et al. solve this problem with the quantitative nuclease protection assay and apply the approach to study subsets of islet cells.
Abstract: http://links.ealert.nature.com/ctt?kn=154&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=145&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
RESOURCES
The transcription unit architecture of the Escherichia coli genome pp1043 - 1049
Byung-Kwan Cho et al.
doi:10.1038/nbt.1582
Abstract: http://links.ealert.nature.com/ctt?kn=156&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=140&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries pp1050 - 1055
Henrike Veith et al.
doi:10.1038/nbt.1581
Abstract: http://links.ealert.nature.com/ctt?kn=100&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=136&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
A third quarter improvement for biotech hiring p1056
Michael Francisco
doi:10.1038/nbt1109-1056
http://links.ealert.nature.com/ctt?kn=148&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
PEOPLE
People p1058
doi:10.1038/nbt1109-1058
http://links.ealert.nature.com/ctt?kn=151&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Lab Offers saves money on lab costs!
Get exclusive discounts on products used in your lab: cell cultures, antibodies, lab consumables, imaging equipment, DNA and RNA isolation products, gene targeting equipment, centrifuges, and so much more.
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=57&m=34377268&r=MTc3MTg2NzE2NgS2&b=2&j=NjA1Nzk3MTES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
